Immunotherapy with Dendritic Cells as a Cancer Treatment: Perspectives and Therapeutic Potential
Recent Patents on Endocrine Metabolic & Immune Drug Discovery,
Andre A.R. Aleixo, Márcia A. Michelin and Eddie F.C. MurtaAffiliation:
Oncology Research Institute (IPON)/ Discipline of Gynecology and Obstetrics, (UFTM), Avenida Getulio Guarita, sn, Uberaba (MG), CEP 38025-440, Bairro Abadia, Brazil.
AbstractThe immune system, which is indispensible for controlling neoplasias, relies on its innate and acquired immunity components to mount an effective response against tumors. In this context, dendritic cells (DCs) are seen as the best antigen-presenting cells because of their capacity for cross-presentation, which can activate both T-helper and cytotoxic lymphocytes. Thus immunotherapy with DCs is considered promising, especially for early-stage cancers. This article provides a clarifying review of recent perspectives on the development of cancer immunotherapy, which has a wide potential for therapeutic applications, and of patents related to immunotherapy with DCs.
Cancer, dendritic cells, immunotherapy, immune response, therapeutic potential, tumor.
Purchase Online Order Reprints Order Eprints Rights and Permissions